Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089Phase 2Recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Jul 2025
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of db-1311 in solid tumor, sponsored by Duality Biotherapeutics. Started Jul 2025; status: recruiting.
02
Drugs
db-1311
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06953089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953089.